JP2016505019A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505019A5
JP2016505019A5 JP2015552887A JP2015552887A JP2016505019A5 JP 2016505019 A5 JP2016505019 A5 JP 2016505019A5 JP 2015552887 A JP2015552887 A JP 2015552887A JP 2015552887 A JP2015552887 A JP 2015552887A JP 2016505019 A5 JP2016505019 A5 JP 2016505019A5
Authority
JP
Japan
Prior art keywords
deuterium
compound according
disease
pharmaceutically acceptable
enriched compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505019A (ja
JP6359563B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011440 external-priority patent/WO2014110558A1/en
Publication of JP2016505019A publication Critical patent/JP2016505019A/ja
Publication of JP2016505019A5 publication Critical patent/JP2016505019A5/ja
Application granted granted Critical
Publication of JP6359563B2 publication Critical patent/JP6359563B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552887A 2013-01-14 2014-01-14 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 Active JP6359563B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361752055P 2013-01-14 2013-01-14
US61/752,055 2013-01-14
US201361786024P 2013-03-14 2013-03-14
US61/786,024 2013-03-14
PCT/US2014/011440 WO2014110558A1 (en) 2013-01-14 2014-01-14 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018116936A Division JP6749364B2 (ja) 2013-01-14 2018-06-20 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体

Publications (3)

Publication Number Publication Date
JP2016505019A JP2016505019A (ja) 2016-02-18
JP2016505019A5 true JP2016505019A5 (enExample) 2017-02-16
JP6359563B2 JP6359563B2 (ja) 2018-07-18

Family

ID=51167442

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015552887A Active JP6359563B2 (ja) 2013-01-14 2014-01-14 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
JP2018116936A Active JP6749364B2 (ja) 2013-01-14 2018-06-20 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018116936A Active JP6749364B2 (ja) 2013-01-14 2018-06-20 ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体

Country Status (6)

Country Link
US (5) US9540340B2 (enExample)
EP (1) EP2943201B2 (enExample)
JP (2) JP6359563B2 (enExample)
AU (1) AU2014205043B2 (enExample)
CA (1) CA2935495C (enExample)
WO (1) WO2014110558A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2420497T1 (sl) 2006-09-26 2016-04-29 Celgene Corporation 5-substituirani kinazolinonski derivati kot sredstva proti raku
CA3109687A1 (en) 2011-03-11 2012-09-20 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
ES2814952T3 (es) * 2012-09-04 2021-03-29 Celgene Corp Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
HRP20171535T1 (hr) * 2013-05-01 2017-11-17 Celgene Corporation Sinteza 3-(5-amino-2-metil-4-oksokinazolin-3(4h)-il)piperidin-2,6-diona
TW201540323A (zh) * 2014-01-15 2015-11-01 Celgene Corp ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
AU2016288246A1 (en) 2015-07-02 2018-02-01 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
CN108473461B (zh) 2016-01-14 2021-06-15 康朴生物医药技术（上海）有限公司 喹唑啉酮衍生物、其制备方法、药物组合物及应用
KR102368555B1 (ko) 2016-12-16 2022-02-28 강푸 바이오파마슈티칼즈 리미티드 조성물, 이의 적용 및 치료 방법
WO2018208123A1 (ko) * 2017-05-12 2018-11-15 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
KR102014478B1 (ko) 2017-05-12 2019-08-26 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
US11773080B2 (en) 2017-12-22 2023-10-03 Salarius Pharmaceuticals, Inc. Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same
WO2021168314A1 (en) * 2020-02-21 2021-08-26 Plexium, Inc. Quinazolinone compounds and related compounds
EP4185380A4 (en) * 2020-07-24 2024-08-21 Inipharm, Inc. Quinazolinone hsd17b13 inhibitors and uses thereof
AU2021377248B2 (en) 2020-11-13 2025-12-18 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof
WO2024108028A1 (en) * 2022-11-16 2024-05-23 Salarius Pharmaceuticals, Inc. Methods of use of deuterium-enriched compounds
WO2024148164A1 (en) * 2023-01-06 2024-07-11 Salarius Pharmaceuticals, Inc Solid forms and methods of use
WO2024220489A1 (en) 2023-04-18 2024-10-24 Salarius Pharmaceuticals, Inc. Deuterium-enriched compound for use in a method of treatment of multiple myeloma

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4421865A (en) 1981-06-08 1983-12-20 Standard Oil Company (Sohio) Selective hydrogen-deuterium interchange using ion exchange resins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5149820A (en) 1987-03-11 1992-09-22 Norsk Hydro A.S. Deuterated compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
DE69739802D1 (de) 1996-07-24 2010-04-22 Celgene Corp Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
CA2321920C (en) 1998-03-16 2010-05-25 Hon-Wah Man 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
AU2002343220A1 (en) 2001-11-09 2003-05-19 Matsushita Electric Industrial Co., Ltd. Moving picture coding method and apparatus
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20110116225A (ko) 2003-12-02 2011-10-25 셀진 코포레이션 혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CN1956718A (zh) 2004-03-22 2007-05-02 细胞基因公司 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
AU2004319758A1 (en) 2004-04-14 2005-11-24 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
MXPA06012278A (es) 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar.
WO2006053160A2 (en) 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
BRPI0518282A2 (pt) 2004-11-23 2008-11-11 Celgene Corp uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
KR20070090227A (ko) 2004-12-01 2007-09-05 셀진 코포레이션 면역조절 화합물을 포함하는 조성물 및 이의 면역결핍성장애의 치료를 위한 용도
US20060270707A1 (en) 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
BRPI0612803A2 (pt) 2005-06-30 2012-10-02 Celgene Corp processo para preparar um composto
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
ES2359162T3 (es) 2005-09-01 2011-05-19 Celgene Corporation Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas.
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2007041630A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US20080064876A1 (en) 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
BRPI0716092A2 (pt) 2006-08-30 2013-09-17 Celgene Corp composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
JP5567339B2 (ja) 2006-09-15 2014-08-06 セルジーン コーポレイション Ｎ−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法
SI2420497T1 (sl) * 2006-09-26 2016-04-29 Celgene Corporation 5-substituirani kinazolinonski derivati kot sredstva proti raku
EP2142534B1 (en) 2007-03-20 2016-08-10 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
WO2009015028A1 (en) 2007-07-20 2009-01-29 Auspex Pharmaceuticals, Inc. Substituted cyclohexenes
KR100879636B1 (ko) * 2007-08-22 2009-01-21 한국과학기술연구원 세로토닌 ５―ｈｔ₃ａ 길항적 효과를 갖는 퀴나졸린유도체 함유 약제 조성물
US8288414B2 (en) 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
US8354417B2 (en) 2007-09-26 2013-01-15 Celgene Corporation Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
US8492395B2 (en) 2007-09-26 2013-07-23 Celgene Corporation 7-substituted quinazolinone compounds and compositions comprising the same
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
CA2710196A1 (en) 2007-12-20 2009-07-09 Celgene Corporation Use of micro-rna as a biomarker of immunomodulatory drug activity
JP2011510983A (ja) 2008-01-29 2011-04-07 セルジーン コーポレイション Ｃｄ５９のレベルを調節するための、免疫調節化合物を使用する方法
US20090232796A1 (en) 2008-02-20 2009-09-17 Corral Laura G Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
US20090298882A1 (en) 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
EP3354646A1 (en) 2008-10-29 2018-08-01 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
MX2011005112A (es) * 2008-11-14 2011-06-16 Concert Pharmaceuticals Inc Derivados de dioxopiperidinil-ftalimida sustituida.
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
WO2010093605A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of thalidomide
US20120322799A1 (en) 2009-11-30 2012-12-20 Pharmatrophix, Inc. Deuterated compounds useful for treating neurodegenerative diseases
MX2012007217A (es) 2009-12-22 2012-07-10 Celgene Corp Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapeuticos.
TR201903027T4 (tr) 2010-02-11 2019-03-21 Celgene Corp Arilmetoksi izoindolin türevleri ve bunları içeren kompozisyonlar ve bunları kullanma yöntemleri.
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
CA2818361A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals, Inc. 3'-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CA3109687A1 (en) 2011-03-11 2012-09-20 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
PH12013501837A1 (en) * 2011-03-11 2013-11-18 Celgene Corp Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP2702410A2 (en) * 2011-04-29 2014-03-05 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3904875B1 (en) 2012-06-29 2024-11-20 Celgene Corporation Methods for determining drug efficacy using ikzf3 (aiolos)
IN2015DN00845A (enExample) 2012-08-09 2015-06-12 Celgene Corp
CA2878954C (en) 2012-08-09 2020-12-08 Benjamin M. Cohen Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
NZ628077A (en) 2012-08-09 2017-04-28 Celgene Corp Treatment of immune-related and inflammatory diseases
ES2814952T3 (es) * 2012-09-04 2021-03-29 Celgene Corp Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
JP6306592B2 (ja) 2012-09-10 2018-04-04 セルジーン コーポレイション 局所進行乳癌を治療するための方法
AU2014205043B2 (en) * 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives

Similar Documents

Publication Publication Date Title
JP2016505019A5 (enExample)
JP2016508505A5 (enExample)
RU2018126793A (ru) Тетрагидропиранил амино-пирролопиримидинон и способы его применения
RU2013156687A (ru) Антагонисты рецептора св1
JP2018518537A5 (enExample)
JP2015502979A5 (enExample)
JP2019031560A5 (enExample)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2016506916A5 (enExample)
RU2015137757A (ru) Производные пиридазинон-амидов
JP2016532657A5 (enExample)
JP2016534063A5 (enExample)
JP2015511609A5 (enExample)
JP2018537535A5 (enExample)
HRP20190733T1 (hr) Formulacije (s)-3-(4-((4-(morfolinometil)benziloksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona
JP2019529444A5 (enExample)
RU2013144579A (ru) Ингибиторы киназы mst1 и способы их применения
CN108601952B (zh) 雷公藤内酯的葡萄糖缀合物、类似物及其用途
CN110248662A (zh) 一种治疗前列腺癌的组合、药物组合物及治疗方法
JP2017514910A5 (enExample)
JP2015529234A5 (enExample)
JP2019535723A5 (enExample)
JP2021501151A5 (enExample)
JP2020504716A5 (enExample)
JP2019504087A5 (enExample)